Skip to main content
. Author manuscript; available in PMC: 2007 Dec 10.
Published in final edited form as: Oncogene. 2006 Dec 18;26(24):3532–3540. doi: 10.1038/sj.onc.1210143

Figure 4. BMS-387032 activates the cloned p57 promoter dependent upon E2F1.

Figure 4

Figure 4

A. H1299 cells were transfected in triplicate with the indicated promoter-reporter vectors, with (+ E2F1) or without an E2F1 expression vector, as indicated. Twenty-four hours following transfection cells were treated with 500 nM BMS-387032 (+ BMS) or not. Cells were harvested 48 hrs after transfection for determination of luciferase levels. The 5’-end of each p57 promoter constructs is indicate and the 3’ boundary for each is at +14, as indicated. B. This schematic indicates three potential E2F1 binding cites in the p57 promoter (not to scale). Relative basal activities (setting −1552/+14 to 100%) are indicated. C. Constructs described in B were transfected into H1299 cells with or without BMS-387032 or E2F1, as in A. To allow comparison of relative response each reporter is normalized to its own basal activity. D. H1299 cells or E2F1-deficient derivate cells were transfected/treated, as indicated, revealing that BMS-387032 cannot activate the p57 promoter in absence of E2F1. E. H1299 cells were transfected as in A with a series of E2F family expression vectors, as indicated (Cress et al., 1993; Cress & Nevins, 1994).